Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients

NCT01476475 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01476475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01476475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
December 31, 2012
Enrollment
323 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus